Cogent Biosciences (COGT) to Release Quarterly Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT) is anticipated to issue its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect the company to announce earnings of ($0.51) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 9:30 AM ET.

Cogent Biosciences Trading Down 0.5%

NASDAQ COGT opened at $36.53 on Tuesday. The company has a current ratio of 6.38, a quick ratio of 6.38 and a debt-to-equity ratio of 0.23. The business has a fifty day simple moving average of $37.78 and a 200 day simple moving average of $25.58. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $43.73. The firm has a market capitalization of $5.20 billion, a P/E ratio of -22.27 and a beta of 0.45.

Insider Transactions at Cogent Biosciences

In other Cogent Biosciences news, Director Fairmount Funds Management Llc sold 3,500,000 shares of the stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $36.40, for a total transaction of $127,400,000.00. Following the completion of the transaction, the director directly owned 5,503,418 shares of the company’s stock, valued at approximately $200,324,415.20. This represents a 38.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Evan Kearns sold 65,000 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $38.70, for a total value of $2,515,500.00. Following the completion of the sale, the insider directly owned 109,398 shares of the company’s stock, valued at $4,233,702.60. This represents a 37.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 3,737,642 shares of company stock worth $136,600,345 in the last ninety days. Company insiders own 7.29% of the company’s stock.

Institutional Investors Weigh In On Cogent Biosciences

Several institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. increased its stake in shares of Cogent Biosciences by 41.4% in the second quarter. Osaic Holdings Inc. now owns 4,550 shares of the technology company’s stock worth $33,000 after purchasing an additional 1,333 shares in the last quarter. Strs Ohio bought a new position in Cogent Biosciences in the 1st quarter worth approximately $36,000. Global Retirement Partners LLC purchased a new position in Cogent Biosciences in the 4th quarter valued at approximately $37,000. PNC Financial Services Group Inc. raised its holdings in Cogent Biosciences by 414.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,281 shares of the technology company’s stock valued at $46,000 after acquiring an additional 1,032 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its holdings in Cogent Biosciences by 16.1% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 2,159 shares of the technology company’s stock valued at $77,000 after acquiring an additional 300 shares during the period.

Analysts Set New Price Targets

A number of research firms recently weighed in on COGT. Needham & Company LLC reissued a “hold” rating on shares of Cogent Biosciences in a research report on Monday, December 8th. Robert W. Baird increased their price objective on shares of Cogent Biosciences from $14.00 to $34.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cogent Biosciences in a research report on Monday, December 29th. Wall Street Zen lowered Cogent Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, UBS Group upgraded Cogent Biosciences to a “strong-buy” rating in a report on Wednesday, January 7th. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.55.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.